SUNNYVALE, California, April 25, 2026, 13:04 (PDT)
Shares of Intuitive Surgical finished Friday in positive territory, pushing their rebound further after the company raised its 2026 growth forecast and flagged increased demand for its da Vinci surgical systems. According to LSEG data, the stock wrapped up April 24 at $482.22, climbing from $451.29 on April 21.
Why does it matter? Intuitive remains the bellwether for robotic-assisted surgery—still largely driven by hospital capital budgets, how quickly surgeons get on board, and steady sales of single-use tools for every case. Investors are trying to square a stronger quarter with the pricey shares, plus some new headwinds out of China, Japan, and the bariatric space.
Intuitive reported a 23% jump in first-quarter revenue to $2.77 billion. Adjusted earnings climbed, hitting $2.50 a share—up from $1.81 last year. The company installed 431 da Vinci surgical systems during the quarter, 232 of them the latest da Vinci 5 model, bringing the global installed base up 12% to 11,395 units at the end of March.
The company lifted its 2026 global da Vinci procedure growth outlook to a range of 13.5% to 15.5%, nudging higher from the earlier 13% to 15% forecast. That fresh guidance edged past the 15% analysts had penciled in, according to Bloomberg.
Chief Executive Dave Rosa pointed to “expanded adoption of our da Vinci, Ion, and digital platforms” in the company’s statement for the quarter. On the call, Rosa put total procedures up 17%. Da Vinci procedures climbed 16% to 847,000, while Ion procedures jumped 39%, hitting 43,000. Ion is Intuitive’s robotic system for lung biopsies and other airway work. Intuitive Surgical
Chief Financial Officer Jamie Samath cited pricing and the launch of new products as key factors. “Revenue growth ahead of total procedure growth reflects in large part the differentiating value of da Vinci 5,” he told analysts, while noting that gross margins remain tied to tariffs, pricing, product mix, and trade-in volumes. Investing.com
Despite sluggish bariatric volumes and muted demand in Asia, Intuitive Surgical keeps beating expectations, William Blair’s Brandon Vasquez noted in a client memo cited by Investor’s Business Daily. Vasquez is sticking with his outperform call on the shares.
Competition is now tangible. In its filing, Intuitive named Johnson & Johnson and Medtronic as companies that have either rolled out, or announced plans for, robotic-assisted medical procedure systems. Intuitive also pointed to local rivals in China’s robotic surgery market, noting that tender activity and pricing pressure there have dampened demand.
Still, the risks here aren’t negligible. Intuitive reported that U.S. da Vinci bariatric procedures dropped roughly 10% in the first quarter. Outside the U.S., procedures increased 19%, but that’s a step down from the 24% growth seen a year ago. Growth in China and Japan trailed the company’s overall pace, with fewer system placements weighing on recent results.
Tariffs are weighing, too. Intuitive pegged the hit from tariffs and related trade actions at roughly $28 million added to its first-quarter cost of revenue. The company also flagged the risk—any shifts in tariff rates or fresh tariffs could significantly affect its results.
Right now, investors are hanging onto a straightforward pitch: more procedures, an uptick in da Vinci 5 installations, plus a higher forecast. The tougher question looms—can that pace keep beating back hospital budget strains, China rivals, and a valuation that doesn’t allow for much error?
